NCT02712359View on ClinicalTrials.gov

This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama

NACompletedINTERVENTIONAL
Enrollment

1,201

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

August 22, 2018

Study Completion Date

August 22, 2018

Conditions
Hepatitis A Vaccine
Interventions
OTHER

Blood sample collection

A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).

Trial Locations (3)

Unknown

GSK Investigational Site, Chiriquí

GSK Investigational Site, Juán Diaz

GSK Investigational Site, Panama City

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02712359 - This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama | Biotech Hunter | Biotech Hunter